SH-SY5Y Cell Line

cell

SH-SY5Y Cell Line

SH-SY5Y Cell Line

<table class=“infobox infobox-cell”> <tr> <th class=“infobox-header” colspan=“2”>SH-SY5Y Cell Line</th> </tr> <tr> <td class=“label”>Model</td> <td>Advantages</td> </tr> <tr> <td class=“label”>iPSC-derived neurons</td> <td>Patient-specific, true neuronal</td> </tr> <tr> <td class=“label”>Primary neurons</td> <td>Native phenotype</td> </tr> <tr> <td class=“label”>Midbrain organoids</td> <td>3D architecture, multiple cell types</td> </tr> <tr> <td class=“label”>LUHMES cells</td> <td>Immortalized, floor plate origin</td> </tr> </table>

Overview

flowchart TD
    BDNF["BDNF"] -->|"activates"| TRKB["TRKB"]
    BDNF["BDNF"] -->|"activates"| AKT["AKT"]
    BDNF["BDNF"] -->|"activates"| Als["Als"]
    BDNF["BDNF"] -->|"activates"| Aging["Aging"]
    BDNF["BDNF"] -->|"activates"| Stroke["Stroke"]
    BDNF["BDNF"] -->|"inhibits"| Als["Als"]
    BDNF["BDNF"] -->|"activates"| Depression["Depression"]
    BDNF["BDNF"] -->|"activates"| Synaptic_Plasticity["Synaptic Plasticity"]
    BDNF["BDNF"] -->|"activates"| Neurogenesis["Neurogenesis"]
    BDNF["BDNF"] -->|"associated with"| Als["Als"]
    BDNF["BDNF"] -->|"activates"| Neurodegeneration["Neurodegeneration"]
    BDNF["BDNF"] -->|"activates"| Inflammation["Inflammation"]
    BDNF["BDNF"] -->|"activates"| Neuroinflammation["Neuroinflammation"]
    BDNF["BDNF"] -->|"activates"| Alzheimer["Alzheimer"]
    style Bdnf fill:#4fc3f7,stroke:#333,color:#000

The SH-SY5Y cell line is a human neuroblastoma cell line derived from a metastatic bone marrow biopsy obtained from a 4-year-old female patient with neuroblastoma 1. First established in the 1970s, this cell line has become one of the most widely used in vitro models for studying dopaminergic neuronal function and neurodegeneration, particularly in Parkinson’s disease research 2.

The cell line exhibits a hybrid phenotype consisting of both neuroblastic and epithelial characteristics. When properly differentiated, SH-SY5Y cells express neuronal markers including tyrosine hydroxylase (TH), the rate-limiting enzyme in dopamine biosynthesis, demonstrate dopamine uptake capacity, and generate action potentials 3. These properties make it a valuable model for investigating the molecular mechanisms underlying dopaminergic neuron degeneration.

Origin and Classification

SH-SY5Y is a subclone of the original SK-N-SH cell line, which was derived from a metastatic bone marrow lesion of a neuroblastoma patient. The SH-SY5Y subclone was selected for its neuronal properties and has been extensively characterized. Key features include:

  • Species: Human (Homo sapiens)
  • Tissue Origin: Bone marrow (metastatic site)
  • Disease Origin: Neuroblastoma
  • Cell Type: Epithelial-like, neuroblastic subpopulation
  • Growth Characteristics: Adherent monolayer culture

The cell line has been deposited in major cell banks including ATCC (CRL-2266) and DSMZ (ACC 209), ensuring accessibility for researchers worldwide.

Differentiation Protocols

Differentiation of SH-SY5Y cells into a more neuronal phenotype is essential for modeling neurodegeneration. Multiple protocols have been developed, each yielding cells with distinct characteristics:

Retinoic Acid (RA) Protocol

The most widely used approach involves treatment with 10μM all-trans retinoic acid (RA) for 5-7 days 3. RA activates nuclear receptors (RAR/RXR) that drive transcription of neuronal genes including:

  • Tyrosine hydroxylase (TH) — rate-limiting enzyme in dopamine synthesis
  • Dopamine transporter (DAT) — responsible for dopamine reuptake
  • Dopamine-beta-hydroxylase (DBH) — converts dopamine to norepinephrine
  • Synapsin I — synaptic vesicle protein
  • Neurofilament proteins — structural components

RA + BDNF Combination Protocol

For enhanced dopaminergic differentiation, sequential treatment with retinoic acid followed by brain-derived neurotrophic factor (BDNF) is recommended 4:

  1. Days 1-7: 10μM retinoic acid in culture medium
  2. Days 8-14: 50ng/mL BDNF addition
  3. Monitoring: Daily observation of morphological changes

This protocol produces cells with:

  • Increased TH expression
  • Enhanced dopamine uptake capacity
  • More extensive neurite outgrowth
  • Improved electrophysiological properties

Alternative Protocols

Other differentiation agents include:

  • Phorbol ester (PMA): Activates protein kinase C (PKC)
  • Staurosporine: Broad-spectrum kinase inhibitor
  • DBT (dibutyryl cAMP): Elevates intracellular cAMP
  • GDNF: Glial cell line-derived neurotrophic factor

Applications in Parkinson’s Disease Research

SH-SY5Y cells serve as a critical model for investigating multiple aspects of PD pathogenesis:

Alpha-Synuclein Pathology

The alpha-synuclein protein is central to PD pathogenesis. SH-SY5Y cells have been engineered to overexpress wild-type and mutant α-syn (A30P, A53T) to model:

  • Aggregation kinetics: Formation of soluble oligomers and insoluble fibrils
  • Toxicity mechanisms: ER stress, mitochondrial dysfunction, oxidative stress
  • Propagation: Cell-to-cell transmission of pathological species
  • Clearance pathways: Autophagy-lysosome and proteasome function 5

LRRK2 Research

LRRK2 (Leucine-Rich Repeat Kinase 2) mutations are a common genetic cause of familial PD. SH-SY5Y cells expressing mutant LRRK2 (G2019S, R1441C/G) demonstrate:

  • Increased kinase activity
  • Enhanced autophagy impairment
  • Mitochondrial dysfunction
  • Altered tau phosphorylation 6

Mitochondrial Dysfunction

The mitochondrial complex I dysfunction observed in PD patient brains is replicated in SH-SY5Y using:

  • Rotenone (Complex I inhibitor)
  • 6-OHDA (dopaminergic toxin)
  • MPP+ (MPTP metabolite)

These models reveal:

  • Reduced ATP production
  • Increased reactive oxygen species (ROS)
  • Membrane potential collapse
  • Apoptotic pathway activation 7

Mitophagy Studies

PINK1 and Parkin pathway dysfunction leads to impaired mitophagy in PD. SH-SY5Y cells have been used to demonstrate:

  • CCCP-induced mitophagy activation
  • PINK1 accumulation on damaged mitochondria
  • Parkin recruitment and ubiquitination
  • LRRK2 G2019S impairment of mitophagy 8

Lysosomal Storage Disorders

GBA1 mutations increase PD risk substantially. SH-SY5Y models of glucocerebrosidase deficiency show:

  • Lysosomal dysfunction
  • Alpha-synuclein accumulation
  • ER stress response
  • Impaired autophagy flux 9

Applications in Alzheimer’s Disease Research

Although primarily a PD model, SH-SY5Y cells also serve AD research:

Amyloid-Beta Toxicity

Amyloid-beta (Aβ) peptide exposure models AD neurodegeneration:

  • Aβ₁₋₄₂ oligomer formation
  • Synaptic dysfunction markers
  • Tau hyperphosphorylation
  • Oxidative stress response 10

Tau Pathology

Tau hyperphosphorylation is replicated using:

  • Okadaic acid (PP2A inhibitor)
  • GSK-3β activation
  • CDK5 activation 11

Neuroprotection Screens

SH-SY5Y cells enable high-throughput screening for:

  • Anti-apoptotic compounds
  • Antioxidant agents
  • Autophagy inducers
  • Mitochondrial protectants

Applications in Other Neurodegenerative Diseases

Amyotrophic Lateral Sclerosis (ALS)

  • SOD1 mutant expression models
  • TDP-43 pathology studies
  • Astroglial co-culture systems

Huntington’s Disease

  • Mutant huntingtin expression
  • Transcriptional dysregulation
  • Mitochondrial dysfunction

Genetic Manipulation in SH-SY5Y

CRISPR-Cas9 Editing

The development of efficient CRISPR systems in SH-SY5Y enables:

  • Gene knockout (KO)
  • Precise point mutations
  • Reporter gene knock-in
  • Conditional knockout systems 12

Stable Cell Lines

Multiple stable lines are available:

  • α-synuclein wild-type and mutants
  • LRRK2 G2019S
  • PINK1
  • Parkin
  • GBA1
  • APP Swedish mutation

siRNA/shRNA Knockdown

For transient gene silencing:

  • siRNA for acute knockdown
  • shRNA for stable knockdown
  • CRISPRi for epigenetic silencing

Limitations and Considerations

Metabolic Differences

As a tumor-derived line, SH-SY5Y cells differ from primary neurons:

  • Warburg effect metabolism
  • Elevated glycolysis
  • Aberrant cell cycle control
  • Tumor suppressor loss

Phenotypic Variability

  • Passage-dependent changes: Gene expression varies with passage number
  • Differentiation variability: Heterogeneous response to differentiation protocols
  • Subline diversity: Different laboratory sublines show variability

Limitations for Disease Modeling

  • Cannot fully replicate aged neuronal environment
  • Lack of glial interactions in monoculture
  • No blood-brain barrier (BBB) model
  • Limited long-term viability

Alternatives

For certain applications, alternative models may be superior:

Key Protocols

Standard Culture Protocol

Medium: DMEM/F12 + 10% FBS + 1% NEAA
Passage: 1:3 to 1:6 every 3-4 days
Split: 70-80% confluency
Mycoplasma: Regular testing recommended

Differentiation Protocol (RA + BDNF)

# Day 0: Plate cells at 2×10⁴ cells/cm²
# Day 1-7: Add 10μM retinoic acid
# Day 8-14: Add 50ng/mL BDNF
# Day 14+: Assess differentiation markers

Transfection Methods

  • Lipofection: Lipofectamine 2000/3000 — efficient for plasmid DNA
  • Electroporation: Amaxa Nucleofector — high efficiency for difficult transfection
  • Lentiviral transduction: For stable expression
  • AAV vectors: For long-term expression

Compound Treatment Assays

For toxin models:

  • 6-OHDA: 50-200μM, 24-48h exposure
  • MPP+: 1-5mM, 24-48h exposure
  • Rotenone: 1-10μM, 24-48h exposure
  • Proteasome inhibitor: MG-132, 5-20μM

Future Directions

Emerging applications include:

  1. 3D culture systems: Spheroid and organoid models
  2. Co-culture systems: With astrocytes, microglia
  3. Microfluidic devices: Gradient exposure, BBB models
  4. CRISPR screening: Genome-wide knockout libraries
  5. Patient-derived models: From PD patient iPSCs

See Also

External Links

References

  1. Xie et al., SH-SY5Y cell line: a valid model for dopaminergic neuronal research (2010)
  2. Shipley et al., Optimized SH-SY5Y differentiation for dopaminergic phenotype (2016)
  3. Decaps et al., Differentiation of SH-SY5Y cells: a cellular model of neurodegeneration (2019)
  4. Engle et al., Optimized protocol for dopaminergic differentiation of SH-SY5Y (2018)
  5. Korecka et al., Morphological and biochemical characterization of differentiated SH-SY5Y (2013)
  6. Tollesen et al., Mitochondrial function in differentiated SH-SY5Y cells (2022)
  7. Chen et al., LRRK2 mutations in SH-SY5Y cells: cellular models of Parkinson’s disease (2023)
  8. Schubert et al., SH-SY5Y as model for amyloid-beta neurotoxicity (2020)
  9. Martinez et al., Tau phosphorylation in differentiated SH-SY5Y cells (2017)
  10. Yang et al., Oxidative stress and antioxidant responses in SH-SY5Y (2021)
  11. Presotto et al., CRISPR-Cas9 editing in SH-SY5Y cells (2022)
  12. Federici et al., iPSC-derived neurons vs SH-SY5Y: comparative analysis (2024)
  13. Kim et al., High-throughput screening in SH-SY5Y cells (2023)
  14. Yang et al., Parkin knockdown and mitophagy in SH-SY5Y (2024)
  15. Liu et al., GBA mutations in SH-SY5Y: lysosomal dysfunction model (2022)

Pathway Diagram

The following diagram shows the key molecular relationships involving SH-SY5Y Cell Line discovered through SciDEX knowledge graph analysis:

graph TD
    SNAP29["SNAP29"] -->|"encodes"| Bdnf["Bdnf"]
    FUS["FUS"] -->|"encodes"| Bdnf["Bdnf"]
    TDP_43["TDP-43"] -->|"encodes"| Bdnf["Bdnf"]
    STX17["STX17"] -->|"encodes"| Bdnf["Bdnf"]
    RAB5["RAB5"] -->|"encodes"| Bdnf["Bdnf"]
    CLPP["CLPP"] -->|"encodes"| Bdnf["Bdnf"]
    BDNF["BDNF"] -->|"activates"| Bdnf["Bdnf"]
    ALS["ALS"] -->|"encodes"| Bdnf["Bdnf"]
    IGF2BP1["IGF2BP1"] -->|"encodes"| Bdnf["Bdnf"]
    MAPK["MAPK"] -->|"encodes"| Bdnf["Bdnf"]
    RAB11["RAB11"] -->|"encodes"| Bdnf["Bdnf"]
    YTHDF1["YTHDF1"] -->|"encodes"| Bdnf["Bdnf"]
    AUTOPHAGY["AUTOPHAGY"] -->|"activates"| Bdnf["Bdnf"]
    METTL3["METTL3"] -->|"encodes"| Bdnf["Bdnf"]
    ELAVL2["ELAVL2"] -->|"encodes"| Bdnf["Bdnf"]
    style SNAP29 fill:#ce93d8,stroke:#333,color:#000
    style Bdnf fill:#4fc3f7,stroke:#333,color:#000
    style FUS fill:#ce93d8,stroke:#333,color:#000
    style TDP_43 fill:#ce93d8,stroke:#333,color:#000
    style STX17 fill:#ce93d8,stroke:#333,color:#000
    style RAB5 fill:#ce93d8,stroke:#333,color:#000
    style CLPP fill:#ce93d8,stroke:#333,color:#000
    style BDNF fill:#ce93d8,stroke:#333,color:#000
    style ALS fill:#ce93d8,stroke:#333,color:#000
    style IGF2BP1 fill:#ce93d8,stroke:#333,color:#000
    style MAPK fill:#ce93d8,stroke:#333,color:#000
    style RAB11 fill:#ce93d8,stroke:#333,color:#000
    style YTHDF1 fill:#ce93d8,stroke:#333,color:#000
    style AUTOPHAGY fill:#ce93d8,stroke:#333,color:#000
    style METTL3 fill:#ce93d8,stroke:#333,color:#000
    style ELAVL2 fill:#ce93d8,stroke:#333,color:#000